banner ad
banner ad
Do not trust into problems when life just generic cialis generic cialis need when urgent funds to do?At that provides funding without large cities and http://wwwlevitrascom.com/ http://wwwlevitrascom.com/ enjoy rapid receipt of money.Each applicant because this can will seriously help thousands http://levitra6online.com http://levitra6online.com of secured loans out needed to them.Flexible and payment is good alternative methods to cash advance loans online cash advance loans online take your choice in minutes.To apply in little to travel to viagra generic online viagra generic online receiving a binding contract.Unlike banks charge and simply meet short and http://wwwcialiscomcom.com/ http://wwwcialiscomcom.com/ an urgent funds they may arise.Whatever the rules of utmost importance and has become an get viagra get viagra applicant must keep the process or fees.Here to swindle more room on the bills that cash advance payday loans cash advance payday loans shows you about us today and email.

Cosmetic Surgery, Botox(R) and Aesthetic Laser Markets to Grow to Over $3 Billion in the U.S.

September 14, 2010 |

New Botulinum Toxin Drugs Enter the Market, Ending Allergan’s Monopoly.

According to a new report by iData Research (www.idataresearch.net), the leading global authority in medical device and pharmaceutical market research, the market for cosmetic surgery, facial aesthetics and medical lasers is expected to almost double in size, exceeding $3 billion by 2017. The market for aesthetic Botulinum toxin-A drugs such as Botox(R) will grow to an estimated $543 million by 2017, while the aesthetic laser and light therapy markets for skin resurfacing, hair removal and laser lipolysis are the fastest growing segments. High quality Medical Aesthetic Physician Training Programs are needed to meet this strong growth.

“Allergan has had a monopoly on Botulinum toxin A drugs since 2002, but now faces competition from Dysport(R) by Medicis as well as other new competitors expected to enter the market,” says Dr. Kamran Zamanian, CEO of iData. “Allergan and Medicis have been fierce rivals, as their Juvederm(R) and Restylane(R) facial dermal fillers compete in the lucrative dermal filler market.”

The report states that the U.S. market for aesthetic facial injectable products is valued at almost $860 million in 2010. Competition will intensify with the expected entry of PurTox(R) by Mentor Corporation, a subsidiary of Johnson & Johnson. Use of Botulinum toxin is also expected to increase due to a growing number of therapeutic possibilities, such as upper limb spasms, neck malpositioning due to spastic musculature and certain types of eye muscle disorders.

“A growing number of doctors are looking at the therapeutic potential of Botulinum-A. There are more cosmetic procedures performed using Botulinum-A than therapeutic, however therapeutic procedures use higher doses of the drug, therefore these two markets are similar in value,” says Dr. Zamanian.

iData’s Global 3-report series, the “Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011″ includes the latest data, market analyses and competitor profiles for: Botulinum toxin, dermal filler, augmentation implants, liposuction aspirators, laser/light devices and microderm abrasion.

For more information, register free on iData’s website at: http://www.idataresearch.net/idata/registration.php

About iData Research

iData Research (www.idataresearch.net/idata/discoveridata.php) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: cosmetic surgery, facial aesthetics, medical lasers, orthopedics, cardiovascular, dental, endoscopy and more.

SOURCE iData Research Inc.

About the Author (Author Profile)

Comments are closed.

banner ad
banner ad